<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3111">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341142</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0329</org_study_id>
    <nct_id>NCT04341142</nct_id>
  </id_info>
  <brief_title>Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER</brief_title>
  <acronym>COVID-SER</acronym>
  <official_title>Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Covid-SER is a prospective multi-center study for the evaluation of diagnostic performance of
      available serological tests
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2020</start_date>
  <completion_date type="Anticipated">April 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The positivity (Yes/No) of the serological test.</measure>
    <time_frame>Day 0</time_frame>
    <description>The sensitivity and specificity of serological tests (positive or negative) compared to molecular detection of the virus by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The positivity (Yes/No) of the serological test.</measure>
    <time_frame>Day 3</time_frame>
    <description>The sensitivity and specificity of serological tests (positive or negative) compared to molecular detection of the virus by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The positivity (Yes/No) of the serological test.</measure>
    <time_frame>Day 7</time_frame>
    <description>The sensitivity and specificity of serological tests (positive or negative) compared to molecular detection of the virus by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The positivity (Yes/No) of the serological test.</measure>
    <time_frame>Day 14</time_frame>
    <description>The sensitivity and specificity of serological tests (positive or negative) compared to molecular detection of the virus by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The positivity (Yes/No) of the serological test.</measure>
    <time_frame>Day 21</time_frame>
    <description>The sensitivity and specificity of serological tests (positive or negative) compared to molecular detection of the virus by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The positivity (Yes/No) of the serological test.</measure>
    <time_frame>Day 28</time_frame>
    <description>The sensitivity and specificity of serological tests (positive or negative) compared to molecular detection of the virus by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The positivity (Yes/No) of the serological test.</measure>
    <time_frame>Day 35</time_frame>
    <description>The sensitivity and specificity of serological tests (positive or negative) compared to molecular detection of the virus by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The positivity (Yes/No) of the serological test.</measure>
    <time_frame>Day 42</time_frame>
    <description>The sensitivity and specificity of serological tests (positive or negative) compared to molecular detection of the virus by PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of IgM and IgG antibody titer at each sampling of weekly and monthly visits of covid-19+ patients and implementation of the kinetics of mean appearance.</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Among the symptomatic PCR negative patients recruited into the study at the first visit, the measurement of the IgM antibody and IgG titer will be performed in serum at D28, and the positive results will then constitute the false-negative PCR results.</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Measurement of IgM and IgG antibody titer at each sampling of late patient visits.</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- The neutralizing capacity of the antibodies will be determined by in vitro serum neutralization tests on seropositive serum. A group of 50 patients made up of seropositive and asymptomatic caregivers at the time of infection will represent this group.</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>CoV2 Positive Caregivers</condition>
  <arm_group>
    <arm_group_label>Serological tests will be applied on patients blood sampling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serological tests will be applied on patients blood sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serological tests will be applied on patients blood sampling</intervention_name>
    <description>Application of tests on patients' serum</description>
    <arm_group_label>Serological tests will be applied on patients blood sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Seropositive caregivers screened for anti-SARS CoV2 antibodies during their
             consultation at the occupational medicine of HCL.

          -  Age: ≥ 18 years old

          -  Persons having given their written consent and accepting a follow-up every 6 months
             for 24 months, followed by a final visit at 36 months.

          -  Persons affiliated to a social security scheme or beneficiary of such a scheme.

        Exclusion Criteria:

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Baptiste Mr FASSIER, Dr</last_name>
    <phone>04 78 86 12 05</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-baptiste.fassier@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lyon Sud,Sainte Eugénie bat 4M,5, Chemin du Grand Revoyet</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

